Gastroenterology Market Set for 5.7% CAGR Growth Through 2032, Reports Persistence Market Research

The global gastroenterology market is witnessing significant expansion, driven by the increasing prevalence of gastrointestinal (GI) disorders across all age groups and the continuous evolution of diagnostic and therapeutic technologies. Valued at US$ 38.46 billion in 2025, the market is projected to grow steadily to US$ 56.54 billion by 2032, registering a compound annual growth rate (CAGR) of 5.7% during the forecast period. Gastroenterology encompasses the diagnosis, treatment, and prevention of disorders affecting the digestive system, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder.

A notable factor behind this market's robust trajectory is the global rise in GI diseases such as Irritable Bowel Syndrome (IBS), ulcerative colitis, Crohn's disease, and colorectal cancer. Increasing consumption of processed foods, urbanization, and sedentary lifestyles have significantly contributed to the burden of digestive health issues. In parallel, advancements in endoscopic imaging, biologics, and artificial intelligence (AI) have revolutionized early diagnosis and precision treatment, leading to improved patient outcomes. The growing acceptance of minimally invasive techniques, such as capsule endoscopy and endoscopic submucosal dissection (ESD), continues to boost the adoption of gastroenterology solutions globally.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35347

North America currently dominates the global gastroenterology market, holding approximately 45% of total revenue share. This leadership can be attributed to the region's strong healthcare infrastructure, higher disease awareness, and widespread adoption of advanced diagnostic tools. The United States remains the leading country within this region due to its aging population, significant R&D investments, and broad availability of biologic therapies. Meanwhile, the Asia Pacific region is poised to witness the fastest growth over the next decade, supported by expanding healthcare access, growing prevalence of GI conditions, and rising medical research investments, particularly in China and India.

Key Highlights from the Report

• The global gastroenterology market is projected to reach US$ 56.54 billion by 2032, expanding at a CAGR of 5.7%.
• Rising prevalence of GI disorders such as IBD, IBS, and colorectal cancer drives the need for advanced therapies.
• Branded drugs dominate the market, contributing to around 76% of total revenue in 2025.
• Generic alternatives are expected to witness the fastest growth due to affordability and accessibility.
• North America leads the global market with strong regulatory support and advanced healthcare systems.
• The integration of AI, telemedicine, and minimally invasive procedures is revolutionizing gastroenterology.

Market Segmentation Analysis

The gastroenterology market is segmented based on product type, disease indication, and end-user.

By Product Type

The market is primarily divided into branded and generic products. The branded segment is expected to command around 76% market share in 2025, driven by innovative drug development, premium pricing, and strong brand reputation. Branded drugs, such as Humira (AbbVie), Entyvio (Takeda), Nexium (AstraZeneca), and RINVOQ (AbbVie), continue to dominate the prescription landscape due to their proven clinical efficacy and physician trust. These products target major gastrointestinal conditions including Crohn's disease, ulcerative colitis, gastroesophageal reflux disease (GERD), and acid reflux.

Meanwhile, the generic segment is projected to record the fastest growth from 2025 to 2032, fueled by patent expirations and growing healthcare cost pressures. Generics such as Omeprazole, Pantoprazole, and Ondansetron are widely adopted due to their cost-effectiveness and comparable therapeutic benefits. Governments in developing regions are increasingly promoting generic drugs through awareness initiatives and reimbursement programs, making them accessible to a broader population.

By Disease Indication / End-User

Within the end-user or disease indication segmentation, Crohn's Disease (CD) holds the leading position, accounting for nearly 40% of total market share in 2025. CD is a chronic inflammatory condition that affects the digestive tract, and its incidence continues to rise globally due to lifestyle factors, genetic predisposition, and environmental triggers. Pharmaceutical advancements, such as biologic therapies and small-molecule inhibitors, have significantly improved the management of CD, contributing to the dominance of this segment.

Ulcerative Colitis (UC) is expected to be the fastest-growing indication, expanding at an estimated CAGR of 4.3% during the forecast period. The rising adoption of biologics, including vedolizumab and infliximab, along with recent drug approvals like mirikizumab (Omvoh) for Crohn's disease and UC, underscore the momentum in this therapeutic area. Ongoing research targeting gut microbiota and immune modulation will further strengthen treatment portfolios in UC and related inflammatory bowel diseases.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/gastroenterology-market.asp

Regional Insights
North America

North America continues to dominate the global gastroenterology market, capturing approximately 45% of total revenue in 2025. The region's growth is primarily attributed to the rising prevalence of GI disorders, robust healthcare infrastructure, and strong presence of major industry players including Medtronic, Boston Scientific, AbbVie, and Stryker. The United States leads the region due to its aging population, rising healthcare spending, and government initiatives aimed at early disease detection and prevention. Active advocacy organizations such as the Crohn's & Colitis Foundation also play a pivotal role in supporting patient awareness and clinical research.

Europe

Europe is witnessing steady growth, underpinned by increasing adoption of minimally invasive procedures, rising geriatric population, and growing awareness of preventive healthcare. Countries like Germany, the U.K., and France are leading contributors, with Germany emerging as a key hub for endoscopic innovation and advanced diagnostics. European companies such as Sequana Medical, Norgine, and Creo Medical, along with global giants like Olympus and Medtronic, are investing heavily in new technologies, including disposable endoscopes and AI-assisted imaging.

Asia Pacific

The Asia Pacific region is forecast to experience the fastest CAGR from 2025 to 2032, driven by rapid healthcare infrastructure expansion, rising disposable incomes, and increasing incidence of GI diseases. Countries like China, India, and Japan are witnessing growing demand for endoscopic procedures and biologic therapies. Local companies such as Takeda Pharmaceutical (Japan) and Livzon Pharmaceutical (China) are expanding their gastroenterology product lines to meet domestic needs. Additionally, government-led healthcare reforms and insurance expansions are improving access to advanced gastroenterology treatments.

Market Drivers

The gastroenterology market's growth is propelled by multiple interrelated drivers. Chief among these is the rising incidence of gastrointestinal disorders globally. Changing dietary patterns, excessive alcohol consumption, obesity, and sedentary lifestyles are key contributors to conditions like IBS, GERD, and colorectal cancer. According to studies published in ScienceDirect and the National Library of Medicine, the prevalence of colorectal cancer among younger adults has been rising alarmingly due to poor dietary habits and reduced physical activity.

Technological advancements have also significantly boosted the market. The integration of AI and machine learning (ML) in diagnostic procedures allows for early detection of abnormalities and accurate interpretation of endoscopic images. Tools such as endoscopic ultrasound (EUS), capsule endoscopy, and robotic-assisted surgeries have made diagnosis and treatment less invasive and more precise. Moreover, the introduction of biologics and biosimilars with fewer side effects is transforming treatment paradigms for chronic inflammatory GI conditions.

Additionally, an aging global population is increasing demand for gastroenterology services, as older adults are more prone to gastrointestinal issues. The growing emphasis on preventive screening, supported by government health initiatives, further enhances market penetration.

Market Restraints

Despite strong growth potential, the gastroenterology market faces several challenges. One of the primary restraints is the high cost of diagnostic and therapeutic procedures, particularly endoscopy. Equipment such as high-definition endoscopes, biopsy valves, and ultrasound systems can cost tens of thousands of dollars, making them inaccessible in resource-limited settings. The maintenance and sterilization of these devices also add to operational expenses, restricting adoption in smaller clinics and emerging economies.

Moreover, treatments for chronic GI diseases often involve costly biologic therapies, such as infliximab or vedolizumab, which can cost several thousand dollars per month. Limited insurance coverage and reimbursement policies in developing regions exacerbate this issue, leading to disparities in treatment accessibility. The overall cost burden-including hospitalizations, laboratory tests, and follow-up care-remains a major hurdle for patients and healthcare providers alike.

Market Opportunities

The future of the gastroenterology market is rich with opportunities driven by technological innovations. The integration of AI, robotics, and telemedicine is creating new possibilities for both diagnosis and treatment. AI-assisted systems like Olympus's EVIS X1 and emerging robotic platforms such as Anthropic's Peek Gastro are enabling clinicians to identify lesions and abnormalities with unprecedented precision. Similarly, advancements in capsule endoscopy-including magnetic drive systems and micro-robotic devices-are opening doors for minimally invasive, patient-friendly diagnostics.

The convergence of telemedicine and 5G technology offers a game-changing opportunity to extend gastroenterology services to underserved regions, allowing remote consultations and second opinions from specialists. Furthermore, emerging research into the gut microbiome, genetic testing, and CRISPR-based therapies is paving the way for personalized medicine approaches in treating GI disorders. Novel therapeutic modalities, such as Endoscopic Full Thickness Resection (EFTR), are expected to play an increasing role in early cancer management. These developments will likely redefine the future landscape of gastroenterology, making it more precise, affordable, and patient-centered.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35347

Company Insights

The global gastroenterology market is moderately fragmented, characterized by the presence of established pharmaceutical and medical device manufacturers investing heavily in innovation and partnerships.

Key Players:
• AbbVie Inc.
• Allergan plc
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• Eisai Co., Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson
• Novartis International AG
• Pfizer Inc.
• Procter & Gamble Co.
• Takeda Pharmaceutical Company Limited

Market Segmentation

By Type

Branded
Generics

By Application

Crohn's Disease
Ulcerative Colitis
Irritable Bowel Syndrome (IBD)
Others

By End-user

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Region

North America
Europe
Asia Pacific
South Asia and Oceania
Latin America
Middle East and Africa

Recent Developments

In January 2025, the U.S. FDA approved Omvoh (mirikizumab-mrkz) by Eli Lilly for treating moderately to severely active Crohn's disease, expanding the treatment options for inflammatory bowel disorders.

In July 2024, Eli Lilly and Company acquired Morphic Holding, Inc., strengthening its position in the chronic disease and gastroenterology market segment.

Conclusion

The global gastroenterology market is at a transformative juncture, shaped by the growing burden of gastrointestinal diseases and rapid technological progress. From biologic therapies and AI-assisted diagnostics to telemedicine and minimally invasive techniques, the sector is evolving toward more personalized and accessible healthcare. While challenges related to cost and equitable access persist, the integration of digital technologies and ongoing research into microbiome and genetic therapies offer promising solutions.

North America will continue to lead the market in the near term, but the Asia Pacific region is emerging as the new growth frontier, supported by expanding healthcare infrastructure and increasing disease awareness. As pharmaceutical giants and medtech innovators continue to collaborate on next-generation solutions, the gastroenterology market is expected to witness not only consistent revenue growth but also a paradigm shift toward precision, prevention, and patient empowerment by 2032.

Read More Related Reports:

Elastography Imaging Market https://www.persistencemarketresearch.com/market-research/elastography-imaging-market.asp
Medical Oncology Software Market https://www.persistencemarketresearch.com/market-research/medical-oncology-software-market.asp
Tissue Culture Reagents Market https://www.persistencemarketresearch.com/market-research/tissue-culture-reagents-market.asp
Spinal Muscular Atrophy (SMA) Treatment Market https://www.persistencemarketresearch.com/market-research/spinal-muscular-atrophy-treatment-market.asp
Bioanalytical Testing Services Market https://www.persistencemarketresearch.com/market-research/bioanalytical-testing-services-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.